Literature DB >> 21092386

Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Elise Caccappolo1, Roy N Alcalay, Helen Mejia-Santana, Ming-X Tang, Brian Rakitin, Llency Rosado, Elan D Louis, Cynthia L Comella, Amy Colcher, Danna Jennings, Martha A Nance, Susan Bressman, William K Scott, Caroline M Tanner, Susan F Mickel, Howard F Andrews, Cheryl Waters, Stanley Fahn, Lucien J Cote, Steven Frucht, Blair Ford, Michael Rezak, Kevin Novak, Joseph H Friedman, Ronald F Pfeiffer, Laura Marsh, Brad Hiner, Andrew D Siderowf, Barbara M Ross, Miguel Verbitsky, Sergey Kisselev, Ruth Ottman, Lorraine N Clark, Karen S Marder.   

Abstract

The cognitive profile of early onset Parkinson's disease (EOPD) has not been clearly defined. Mutations in the parkin gene are the most common genetic risk factor for EOPD and may offer information about the neuropsychological pattern of performance in both symptomatic and asymptomatic mutation carriers. EOPD probands and their first-degree relatives who did not have Parkinson's disease (PD) were genotyped for mutations in the parkin gene and administered a comprehensive neuropsychological battery. Performance was compared between EOPD probands with (N = 43) and without (N = 52) parkin mutations. The same neuropsychological battery was administered to 217 first-degree relatives to assess neuropsychological function in individuals who carry parkin mutations but do not have PD. No significant differences in neuropsychological test performance were found between parkin carrier and noncarrier probands. Performance also did not differ between EOPD noncarriers and carrier subgroups (i.e., heterozygotes, compound heterozygotes/homozygotes). Similarly, no differences were found among unaffected family members across genotypes. Mean neuropsychological test performance was within normal range in all probands and relatives. Carriers of parkin mutations, whether or not they have PD, do not perform differently on neuropsychological measures as compared to noncarriers. The cognitive functioning of parkin carriers over time warrants further study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21092386      PMCID: PMC3366462          DOI: 10.1017/S1355617710001190

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  34 in total

1.  Association between early-onset Parkinson's disease and mutations in the parkin gene.

Authors:  C B Lücking; A Dürr; V Bonifati; J Vaughan; G De Michele; T Gasser; B S Harhangi; G Meco; P Denèfle; N W Wood; Y Agid; A Brice
Journal:  N Engl J Med       Date:  2000-05-25       Impact factor: 91.245

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Parkin mutations are frequent in patients with isolated early-onset parkinsonism.

Authors:  Magali Periquet; Morwena Latouche; Ebba Lohmann; Nina Rawal; Giuseppe De Michele; Sylvain Ricard; Hélio Teive; Valérie Fraix; Marie Vidailhet; David Nicholl; Paolo Barone; Nick W Wood; Salmo Raskin; Jean-François Deleuze; Yves Agid; Alexandra Dürr; Alexis Brice
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

4.  Parkin-proven disease: common founders but divergent phenotypes.

Authors:  S Lincoln; J Wiley; T Lynch; J W Langston; R Chen; A Lang; E Rogaeva; D S Sa; R P Munhoz; J Harris; K Marder; C Klein; G Bisceglio; J Hussey; A West; M Hulihan; J Hardy; M Farrer
Journal:  Neurology       Date:  2003-05-27       Impact factor: 9.910

5.  Non-motor behavioural impairments in parkin-deficient mice.

Authors:  Xin-Ran Zhu; Lyutha Maskri; Christina Herold; Verian Bader; Christine C Stichel; Onur Güntürkün; Hermann Lübbert
Journal:  Eur J Neurosci       Date:  2007-09-20       Impact factor: 3.386

6.  Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease.

Authors:  T Foroud; S K Uniacke; L Liu; N Pankratz; A Rudolph; C Halter; C Shults; K Marder; P M Conneally; W C Nichols
Journal:  Neurology       Date:  2003-03-11       Impact factor: 9.910

7.  Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.

Authors:  Sofia A Oliveira; William K Scott; Eden R Martin; Martha A Nance; Ray L Watts; Jean P Hubble; William C Koller; Rajesh Pahwa; Matthew B Stern; Bradley C Hiner; William G Ondo; Fred H Allen; Burton L Scott; Christopher G Goetz; Gary W Small; Frank Mastaglia; Jeffrey M Stajich; Fengyu Zhang; Michael W Booze; Michelle P Winn; Lefkos T Middleton; Jonathan L Haines; Margaret A Pericak-Vance; Jeffery M Vance
Journal:  Ann Neurol       Date:  2003-05       Impact factor: 10.422

8.  Accuracy of family history data on Parkinson's disease.

Authors:  K Marder; G Levy; E D Louis; H Mejia-Santana; L Cote; H Andrews; J Harris; C Waters; B Ford; S Frucht; S Fahn; R Ottman
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

9.  Familial aggregation of early- and late-onset Parkinson's disease.

Authors:  Karen Marder; Gilberto Levy; Elan D Louis; Helen Mejia-Santana; Lucien Cote; Howard Andrews; Juliette Harris; Cheryl Waters; Blair Ford; Steven Frucht; Stanley Fahn; Ruth Ottman
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

10.  Parkin disease: a phenotypic study of a large case series.

Authors:  Naheed L Khan; Elizabeth Graham; Peter Critchley; Anette E Schrag; Nicholas W Wood; Andrew J Lees; Kailash P Bhatia; Niall Quinn
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

View more
  12 in total

1.  Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Anat Mirelman; Rachel Saunders-Pullman; Deborah Raymond; Christina Palmese; Elise Caccappolo; Laurie Ozelius; Avi Orr-Urtreger; Lorraine Clark; Nir Giladi; Susan Bressman; Karen Marder
Journal:  Parkinsonism Relat Disord       Date:  2014-11-20       Impact factor: 4.891

2.  Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.

Authors:  R N Alcalay; E Caccappolo; H Mejia-Santana; M -X Tang; L Rosado; M Orbe Reilly; D Ruiz; B Ross; M Verbitsky; S Kisselev; E Louis; C Comella; A Colcher; D Jennings; M Nance; S Bressman; W K Scott; C Tanner; S Mickel; H Andrews; C Waters; S Fahn; L Cote; S Frucht; B Ford; M Rezak; K Novak; J H Friedman; R Pfeiffer; L Marsh; B Hiner; A Siderowf; H Payami; E Molho; S Factor; R Ottman; L N Clark; K Marder
Journal:  Neurology       Date:  2012-03-21       Impact factor: 9.910

Review 3.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

4.  Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease.

Authors:  Gian D Pal; Deborah Hall; Bichun Ouyang; Jessica Phelps; Roy Alcalay; Michael W Pauciulo; William C Nichols; Lorraine Clark; Helen Mejia-Santana; Lucia Blasucci; Christopher G Goetz; Cynthia Comella; Amy Colcher; Ziv Gan-Or; Guy A Rouleau; Karen Marder
Journal:  Mov Disord Clin Pract       Date:  2016-01-18

5.  Brain Connectivity Changes in Autosomal Recessive Parkinson Disease: A Model for the Sporadic Form.

Authors:  Elena Makovac; Mara Cercignani; Laura Serra; Mario Torso; Barbara Spanò; Simona Petrucci; Lucia Ricciardi; Monia Ginevrino; Carlo Caltagirone; Anna Rita Bentivoglio; Enza Maria Valente; Marco Bozzali
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

6.  Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.

Authors:  Roy N Alcalay; Elise Caccappolo; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia L Comella; Martha A Nance; Susan B Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin E Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Bradley Hiner; Haydeh Payami; Eric Molho; Stewart A Factor; John G Nutt; Carmen Serrano; Maritza Arroyo; Ruth Ottman; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Karen S Marder
Journal:  JAMA Neurol       Date:  2014-01       Impact factor: 18.302

7.  Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

Authors:  Avner Thaler; Anat Mirelman; Tanya Gurevich; Ely Simon; Avi Orr-Urtreger; Karen Marder; Susan Bressman; Nir Giladi
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

Review 8.  Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease.

Authors:  Dominik Haddad; Ken Nakamura
Journal:  FEBS Lett       Date:  2015-10-23       Impact factor: 4.124

9.  Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation.

Authors:  Madeleine E Sharp; Karen S Marder; Lucien Côté; Lorraine N Clark; William C Nichols; Jean-Paul Vonsattel; Roy N Alcalay
Journal:  Mov Disord       Date:  2013-12-27       Impact factor: 10.338

10.  Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.

Authors:  Cristina Nombela; James B Rowe; Sophie E Winder-Rhodes; Adam Hampshire; Adrian M Owen; David P Breen; Gordon W Duncan; Tien K Khoo; Alison J Yarnall; Michael J Firbank; Patrick F Chinnery; Trevor W Robbins; John T O'Brien; David J Brooks; David J Burn; Roger A Barker
Journal:  Brain       Date:  2014-07-30       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.